Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

Close menu
  • News
  • Products
  • Contact
    • Request More Information
    • Journalists
    • GDPR

    Aidoc granted AI industry-first FDA clearance for triage of incidental pulmonary embolism

    This is the company's 6th FDA clearance and further solidifies its leadership as the most comprehensive acute AI vendor in the market

    Aidoc Logo

    News provided by

    Aidoc

    21 Oct, 2020, 16:00 IDT

    Share this article

    Share this article


    NEW YORK, Oct. 21, 2020 /PRNewswire/ -- Aidoc announced today that the US Food and Drug Administration (FDA) has given regulatory clearance for the commercial use of its triaging and notification algorithms for flagging and communicating incidental pulmonary embolism. Flagging incidental, critical findings is a huge technical challenge due to the varied imaging protocols used and lower incidences of such cases. The ability to prioritize incidental critical conditions accurately is a breakthrough in the value AI can bring to the radiologist workflow. 

    "The most common use case we experienced is for critical unsuspected findings in oncology surveillance patients," said Dr. Cindy Kallman, Chief, Section of CT at Cedars-Sinai Medical Center. "The ability to call the referring physician while the patient is still in the house is huge. We are essentially offering a point-of-care diagnosis of PE for our outpatients. Our referring physicians have been completely wowed by this."

    This recently cleared solution provides an always-on safety net for unexpected cases and will be available alongside Aidoc's five existing FDA cleared tools for the triage and notification of Intracranial Hemorrhage, C-Spine Fractures, Large Vessel Occlusion, Intra Abdominal Free Gas and Pulmonary Embolism. 

    "There's a reason why most AI triage solutions don't focus on incidental findings," said Michael Braginsky, Aidoc's CTO. "Because the prevalence of incidental findings is relatively low, the specificity of the AI must be especially high, otherwise the false positive rate will be excessive and user adoption will be negatively impacted. In addition, an incidental PE algorithm detects PE in non-dedicated exams, where contrast is by definition suboptimal, and there's an extremely high variability of protocols which challenges the AI even further. It was a scientific breakthrough that our team achieved that made this possible."

    Just last month the CMS approved the first reimbursement opportunity for AI – specifically for computer-assisted triage and notification of patients with suspicion of stroke. This is a very positive industry outcome and applies to Aidoc's AI solution for triaging and flagging Large Vessel Occlusions. Aidoc is working to submit other AI solutions to this reimbursement program. 

    Logo - https://mma.prnewswire.com/media/1274791/Aidoc_Logo.jpg

    Media contact:
    Ariella Shoham
    VP Marketing 
    [email protected]

    SOURCE Aidoc

    Modal title

    Also from this source

    Aidoc Appoints Christopher Young as Chief Growth Officer to Accelerate Global Expansion and Enterprise AI Strategy

    Aidoc Appoints Christopher Young as Chief Growth Officer to Accelerate Global Expansion and Enterprise AI Strategy

    Aidoc, a global leader in clinical AI, today announced the appointment of Christopher Young as Chief Growth Officer. Young brings more than 30 years...

    Aidoc Raises $150 Million Series E Led by Goldman Sachs to Scale Clinical AI for Earlier, Safer Diagnoses

    Aidoc Raises $150 Million Series E Led by Goldman Sachs to Scale Clinical AI for Earlier, Safer Diagnoses

    Aidoc, a global leader in clinical AI, has raised $150 million in Series E funding led by Growth Equity at Goldman Sachs Alternatives. The round had...

    More Releases From This Source

    Contact PR Newswire

    • +972-77-2005042
      from 8 AM - 11 PM IL

    Global Sites

    • APAC
    • APAC - Traditional Chinese
    • Asia
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany

     

    • India
    • Indonesia
    • Israel
    • Italy
    • Mexico
    • Middle East
    • Middle East - Arabic
    • Netherlands
    • Norway
    • Poland

     

    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States

    Do not sell or share my personal information:

    • Submit via [email protected] 
    • Call Privacy toll-free: 877-297-8921
    Global Sites
    • Asia
    • Brazil
    • Canada
    • Csezh
    • Denmark
    • Finland
    • France
    • Germany
    • India
    • Israel
    • Italie
    • Mexico
    • Middle East
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States
    +972-77-2005042
    from 8 AM - 11 PM IL
    • Terms of Use
    • Privacy Policy
    • Information Security Policy
    • Site Map
    • Cookie Settings
    Copyright © 2026 Cision US Inc.